MNOV 8-K
Medicinova Inc (MNOV)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form
Current Report
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|||
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
|
|
|||
|
||||
(Address of principal executive offices) |
|
(Zip Code) |
||
Registrant’s telephone number, including area code:
Not applicable.
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
(Title of each class) |
|
(Trading symbol(s)) |
|
(Name of each exchange on which registered) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07 |
Submission of Matters to a Vote of Security Holders. |
MediciNova, Inc. (the “Company”) held its 2023 annual meeting of stockholders on June 13, 2023 (the “Annual Meeting”). The Company filed its definitive proxy statement for the proposals voted upon at the Annual Meeting with the Securities and Exchange Commission on April 26, 2023 (the “Proxy Statement”).
At the close of business on April 19, 2023, the record date of the Annual Meeting, the Company had 49,046,246 shares of common stock issued and outstanding. The holders of a total of 31,299,321 shares of common stock were present at the Annual Meeting, either in person or by proxy, which total constituted a quorum of the issued and outstanding shares on the record date of the Annual Meeting.
Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting
|
(1) |
To elect one Class I Director nominee named below to serve until the 2026 Annual Meeting of stockholders and until their successors have been duly elected and qualified, or, if sooner, until their earlier death, resignation or removal. The named nominee was so elected, with the votes thereon at the Annual Meeting as follows: |
Final Voting Results
|
|
|
|
|
|
|
|
Nominees |
|
For |
|
Against |
Abstain |
|
Broker Non-Vote |
Hideki Nagao |
|
19,685,986 |
|
7,517,392 |
1,380,430 |
|
2,715,513 |
|
(2) |
To ratify the selection of BDO USA, LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023. This proposal was approved, with the votes thereon at the Annual Meeting as follows: |
Final Voting Results
|
|
|
|
|
|
|
For |
|
Against |
|
Abstain |
|
Broker Non-Vote |
27,807,178 |
|
2,362,900 |
|
1,129,243 |
|
- |
|
(3) |
To approve the Company’s 2023 Equity Incentive Plan, as disclosed in the Proxy Statement. This proposal was approved, with the votes thereon at the Annual Meeting as follows: |
Final Voting Results
|
|
|
|
|
|
|
For |
|
Against |
|
Abstain |
|
Broker Non-Vote |
19,200,437 |
|
7,879,289 |
|
1,504,082 |
|
2,715,513 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
MEDICINOVA, INC. |
||
|
|
|
||
|
|
By: |
|
/s/ Yuichi Iwaki |
|
|
|
|
Yuichi Iwaki President and Chief Executive Officer |
Date: June 14, 2023
|
|
|
|
|